Asia Pacific RNAi Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) and Geography

No. of Pages: 133    |    Report Code: TIPRE00015147    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific RNAi Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Asia Pacific RNAi Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Asia Pacific RNAi Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 RNAi Therapeutics in Cancer Therapy
5.2 Market Opportunities
  • 5.2.1 Imaging Modalities for RNAi Therapeutics for RNAi Therapeutics
5.3 Future Trends
  • 5.3.1 Rising Research & Development (R&D) activity
5.4 Impact of Drivers and Restraints

6. Asia Pacific RNAi Therapeutics Market Regional Analysis

6.1 Asia Pacific RNAi Therapeutics Market Overview
6.2 Asia Pacific RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 Asia Pacific RNAi Therapeutics Market Forecast Analysis

7. Asia Pacific RNAi Therapeutics Market Analysis – by Molecule Type

7.1 Small Interfering RNAs
  • 7.1.1 Overview
  • 7.1.2 Small Interfering RNAs: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 MicroRNA
  • 7.2.1 Overview
  • 7.2.2 MicroRNA: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific RNAi Therapeutics Market Analysis – by Application

8.1 Genetic Disorders
  • 8.1.1 Overview
  • 8.1.2 Genetic Disorders: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Oncology
  • 8.2.1 Overview
  • 8.2.2 Oncology: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Neurodegenerative Disorders
  • 8.3.1 Overview
  • 8.3.2 Neurodegenerative Disorders: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Cardiovascular
  • 8.4.1 Overview
  • 8.4.2 Cardiovascular: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Respiratory Disorders
  • 8.5.1 Overview
  • 8.5.2 Respiratory Disorders: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.6 Infectious Diseases
  • 8.6.1 Overview
  • 8.6.2 Infectious Diseases: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.7 Renal Diseases
  • 8.7.1 Overview
  • 8.7.2 Renal Diseases: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9. Asia Pacific RNAi Therapeutics Market Analysis – by Route of Administration

9.1 Intradermal Injections
  • 9.1.1 Overview
  • 9.1.2 Renal Diseases: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Pulmonary Delivery
  • 9.2.1 Overview
  • 9.2.2 Renal Diseases: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Intravenous Injections
  • 9.3.1 Overview
  • 9.3.2 Renal Diseases: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Intraperitoneal Injections
  • 9.4.1 Overview
  • 9.4.2 Renal Diseases: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10. Asia Pacific RNAi Therapeutics Market – Asia-Pacific Analysis

10.1 Asia-Pacific
  • 10.1.1 Asia Pacific RNAi Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
  • 10.1.1.1 Asia Pacific RNAi Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 China: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.1.1 China: Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.1.2 China: Asia Pacific RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.1.3 China: Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.2 India: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.2.1 India: Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.2.2 India: Asia Pacific RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.2.3 India: Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.3 Japan: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.3.1 Japan: Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.3.2 Japan: Asia Pacific RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.3.3 Japan: Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.4 Australia: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.4.1 Australia: Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.4.2 Australia: Asia Pacific RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.4.3 Australia: Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.5 Rest of Asia-Pacific : Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Asia Pacific RNAi Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Benitec Biopharma
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Olix Pharmaceuticals, Inc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 GlaxoSmithKline plc
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Alnylam Pharmaceuticals, Inc.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Arrowhead Pharmaceuticals, Inc
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - A Market

  1. Benitec Biopharma
  2. Olix Pharmaceuticals, Inc.
  3. GlaxoSmithKline plc
  4. Alnylam Pharmaceuticals, Inc.
  5. Arrowhead Pharmaceuticals, Inc
asia-pacific-rnai-therapeutics-market